Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,068 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,062
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Rheumatoid Arthritis131
- Type 1 Diabetes131
- Atopic Dermatitis123
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California498
- Maryland198
- Alabama179
- Florida152
- Arizona150
- Massachusetts118
- New York116
- Texas112
- Illinois82
- Colorado81
Recruiting studies6,068 total
- NCT06829771RecruitingPhase 1/Phase 2
A new drug combined with standard chemo for large B-cell lymphoma
This trial is testing a new drug called TQB2825 given alongside standard chemotherapy (R-CHOP or GemOx) for people with diffuse large B-cell lymphoma (DLBCL) or a related type called grade 3b follicular lymphoma. The goal is to see if adding this new drug is safe and works better than standard treatment alone.
Bengbu, AnhuiAges 18–80 - NCT06830798RecruitingPhase 3
Ravulizumab to prevent delayed graft function after kidney transplant
This study tests an investigational medicine (ravulizumab) given through a vein to see if it can prevent delayed graft function—meaning the new kidney takes longer to start working—after a high-risk kidney transplant. It is for adults on dialysis who are getting a kidney from a donor whose heart stopped or who is considered high-risk.
Phoenix, ArizonaAges 18 years+ - NCT06830031RecruitingPhase 1
C402-CD19-CAR treatment for relapsed or refractory B-cell lymphoma
This trial tests a new CAR-T cell therapy called C402-CD19-CAR for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. The treatment uses your own immune cells to target and kill cancer cells that have a protein called CD19 on their surface.
TianjinAges 18–75 - NCT06826430RecruitingPhase 1
CAR-T cell therapy for severe lupus-related low platelets
This trial tests a new CAR-T cell treatment called Inaticabtagene Autoleucel for people with lupus that causes very low platelet counts (immune thrombocytopenia) that hasn't gotten better with standard treatments. The goal is to see if it can help raise platelet levels.
Beijing, Beijing MunicipalityAges 18–70 - NCT06830759Recruiting
Real-world study of epcoritamab for lymphoma
This study looks at how well epcoritamab works for people with diffuse large B-cell lymphoma or follicular lymphoma who have already tried two or more treatments. Researchers want to see how it works in routine care, not in a strict research setting.
Ciudad Autonoma de Buenos Aire, Buenos AiresAges 18 years+ - NCT06832306Recruiting
Diaphragm pacing for breathing support in ICU
This trial tests a device that helps stimulate the diaphragm to improve breathing in patients who need a ventilator. It's for people with new breathing problems who have been in the ICU on a ventilator for less than 4 days.
La Jolla, CaliforniaAges 18 years+ - NCT06832410RecruitingPhase 3
Testing VX-880 for type 1 diabetes with a kidney transplant
This trial tests a new treatment called VX-880 for people who have had type 1 diabetes for at least 5 years and have already received a kidney transplant. The goal is to see if VX-880 can improve blood sugar control while you continue your current transplant medications.
Philadelphia, PennsylvaniaAges 18–65 - NCT06829784RecruitingPhase 3
Study of TQC2731 for severe asthma
This trial tests an investigational drug called TQC2731 for people with severe asthma that is not well controlled despite high-dose inhaled steroids. The study aims to see if this treatment can reduce asthma attacks.
Bozhou, AnhuiAges 18–75 - NCT06831370RecruitingPhase 4
New treatment for advanced Hodgkin lymphoma in adults in India
This trial tests a combination of the targeted drug brentuximab vedotin with standard chemotherapy (doxorubicin, vinblastine, and dacarbazine) for adults with Stage 3 or 4 Hodgkin lymphoma who have not had previous treatment. It aims to see if this combination works well and is safe.
Vijayawada, Andhra PradeshAges 18 years+ - NCT06829524Recruiting
Study of satralizumab for NMOSD (real world evidence)
This study looks at how well satralizumab works in people with NMOSD (a rare disorder that affects the nerves in your eyes and spine). It is for people who have had recent flare-ups and test positive for a specific antibody (AQP4). You will receive satralizumab and be followed for at least one year to see if your disease stays under control.
Shanghai, Shanghai MunicipalityAges 12 years+ - NCT06832865RecruitingPhase 2
Combination immunotherapy for relapsed multiple myeloma
This trial tests two drugs, elranatamab and isatuximab, given together to people whose multiple myeloma has come back or stopped responding to earlier treatments. The goal is to see if the combination can shrink or control the cancer where other therapies have not worked well.
Boston, MassachusettsAges 18 years+ - NCT06829238RecruitingPhase 4
Metformin to boost immune function in people with a history of drug use
This study tests whether metformin, a common diabetes drug, can help restore immune system balance in people who have used injection drugs in the past. It includes both people living with HIV and those who are HIV-negative.
Birmingham, AlabamaAges 18–64 - NCT06827860RecruitingPhase 2
Talquetamab shot for elderly with relapsed multiple myeloma
This study tests a new drug called talquetamab, given as a shot under the skin, for older adults with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if it can help control the cancer with fewer side effects.
New York, New YorkAges 70 years+ - NCT06832605Recruiting
Mindfulness classes by video to prevent depression relapse
This trial tests an 8-week mindfulness-based cognitive therapy program delivered via video call to help people with a history of depression prevent future episodes. It may help you learn skills to manage low mood and reduce the chance of relapse.
Elche, AlicanteAges 18 years+ - NCT06828991RecruitingPhase 2
Mosunetuzumab for older DLBCL patients with residual ctDNA
This trial tests whether adding a targeted immunotherapy drug called mosunetuzumab after standard chemotherapy can help older adults with DLBCL who still have tiny traces of cancer DNA in their blood. If you qualify, the goal is to reduce the chance of the cancer coming back.
Rochester, New YorkAges 70 years+ - NCT06827782Enrolling by invitationPhase 1
Cord blood CAR-NK cells for relapsed CNS lymphoma
This trial tests a new treatment using specially engineered immune cells from cord blood to target and kill cancer cells in the brain or spine. It is for people whose central nervous system lymphoma has not responded to or has returned after previous treatments.
Hangzhou, ZhejiangAges 18–75 - NCT06828042RecruitingPhase 1/Phase 2
CAR-γδT cells for refractory autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
BeijingAges 18–80 - NCT06034678Recruiting
Food allergy mastery program for teens and their families
This trial tests a program to help teens with food allergies learn more about managing their condition and reduce its impact on daily life. It is for kids ages 10–14 who have had a common food allergy for at least one year.
Washington D.C., District of ColumbiaAges 10–14 - NCT03807128Recruiting
Study for multiple myeloma resistance and relapse changes
This study looks at how multiple myeloma (a bone marrow cancer) changes over time, especially why it becomes resistant to treatment or comes back. It may help researchers learn what drives relapse and could lead to better future treatments.
La Roche-sur-YonAges 18 years+ - NCT05983809Recruiting
Balance and walking rehab using technology for MS
This trial tests a new type of balance and walking training for people with multiple sclerosis. It uses technology to help improve your stability and gait, which may help you move more safely and confidently.
Roma, RMAges 18–65 - NCT06559553RecruitingPhase 1/Phase 2
Selinexor, pegaspargase, and dexamethasone for NK/T-cell lymphoma
This trial tests a combination of three drugs (selinexor, pegaspargase, and dexamethasone) for people with newly diagnosed NK/T-cell lymphoma. It aims to see if this treatment can shrink tumors and be safe.
Zhengzhou, HenanAges 18–70 - NCT06676384RecruitingPhase 4
Testing additional drugs for IgA nephropathy in South Asian patients
This trial is testing if adding another approved drug to standard treatment can slow kidney function decline in people with IgA nephropathy. It aims to find better options for South Asian adults with this condition.
Nadiād, GujaratAges 18–65 - NCT06682130RecruitingPhase 2
Glofitamab before stem cell transplant for relapsed DLBCL
This study tests a drug called glofitamab before a stem cell transplant for people whose DLBCL has come back or not responded after at least two prior treatments. The goal is to see if this combination can help control the lymphoma before the transplant.
Suzhou, JiangsuAges 18–70 - NCT06819176RecruitingPhase 1
Testing a new drug to shrink hidden HIV in people with suppressed virus
This study tests whether adding a new anti-HIV drug called lenacapavir to your regular HIV treatment can shrink the hidden reservoir of virus in your body. This could be a step toward a cure.
Bethesda, MarylandAges 18–75
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,068 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,217 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.